Sandoz Gains An Edge With High-Concentration US Humira Biosimilar

Hyrimoz Version Of Adalimumab Approved By FDA In Citrate-Free 100mg/ml Form

 
• By Dave Wallace

Sandoz has gained a potential advantage ahead of being part of a second wave of Humira biosimilar competition hitting the US, with the firm obtaining FDA approval for its Hyrimoz version of adalimumab in a citrate-free high-concentration formulation.

High low 3D words
Sandoz now has FDA approval for both high and low strength adalimumab • Source: Shutterstock

More from Biosimilars

More from Products